Financial Contrast: Sandoz Group (OTCMKTS:SDZNY) & Vivos Therapeutics (NASDAQ:VVOS)

Vivos Therapeutics (NASDAQ:VVOS) and Sandoz Group (OTCMKTS:SDZNY) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, valuation, institutional ownership and analyst recommendations.

Profitability

This table compares Vivos Therapeutics and Sandoz Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vivos Therapeutics	-127.70%	-2,325.64%	-98.12%
Sandoz Group	N/A	N/A	N/A

Earnings & Valuation

This table compares Vivos Therapeutics and Sandoz Group”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vivos Therapeutics	$19.57 million	0.43	-$21.17 million	($2.14)	-0.29
Sandoz Group	$11.09 billion	3.26	$914.00 million	N/A	N/A

Sandoz Group has higher revenue and earnings than Vivos Therapeutics.

Institutional & Insider Ownership

26.4% of Vivos Therapeutics shares are owned by institutional investors. Comparatively, 0.1% of Sandoz Group shares are owned by institutional investors. 2.1% of Vivos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent ratings and price targets for Vivos Therapeutics and Sandoz Group, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vivos Therapeutics	1	1	2	0	2.25
Sandoz Group	0	1	0	3	3.50

Vivos Therapeutics currently has a consensus price target of $2.75, indicating a potential upside of 350.82%. Given Vivos Therapeutics’ higher possible upside, equities analysts plainly believe Vivos Therapeutics is more favorable than Sandoz Group.

Risk and Volatility

Vivos Therapeutics has a beta of 6.25, suggesting that its stock price is 525% more volatile than the S&P 500. Comparatively, Sandoz Group has a beta of 0.56, suggesting that its stock price is 44% less volatile than the S&P 500.

Summary

Sandoz Group beats Vivos Therapeutics on 8 of the 13 factors compared between the two stocks.

About Vivos Therapeutics

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.

About Sandoz Group

Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company was founded in 1886 and is headquartered in Basel, Switzerland.